Zepbound (tirzepatide) and Wegovy (semaglutide) are both FDA approved injectable medications for chronic weight management in adults with obesity or overweight with at least one weight related condition. The main difference is that Zepbound targets two gut hormones (GLP-1 and GIP) while Wegovy targets only GLP-1, and clinical trials indicate Zepbound may produce greater average weight loss.

Key Takeaways

  • Both Zepbound and Wegovy are GLP-1 receptor agonists used for weight loss, but Zepbound also activates the GIP receptor.
  • In head to head trials, Zepbound led to an average weight loss of 15% to 20% of body weight after 72 weeks, compared to about 12% to 15% for Wegovy.
  • Both medications require weekly injections and a reduced calorie diet and increased physical activity.
  • Side effects are similar and include nausea, diarrhea, vomiting, and constipation.
  • Cost and insurance coverage vary; Zepbound was approved later and may have different formulary placement.

What are Zepbound and Wegovy?

Zepbound and Wegovy are both injectable prescription medications for chronic weight management. Zepbound contains tirzepatide, which is a dual agonist of GLP-1 and GIP receptors. Wegovy contains semaglutide, which is a GLP-1 receptor agonist only. For a deeper look at how these drug classes work, see our explanation of GLP-1 Medications Explained.

Are Zepbound and Wegovy the same medication?

No, Zepbound and Wegovy are different medications with different active ingredients and mechanisms of action. Zepbound uses tirzepatide, a dual agonist, while Wegovy uses semaglutide, a single agonist. Both are approved for weight management but have distinct clinical profiles.

Which medication leads to more weight loss?

Clinical trials suggest Zepbound tends to produce greater average weight loss. In the SURMOUNT-1 trial, people taking the highest dose of tirzepatide lost an average of 22.5% of their body weight after 72 weeks. In the STEP 1 trial, people taking semaglutide lost an average of 14.9% after 68 weeks. A direct comparison study (SURMOUNT-5) found that tirzepatide led to about 20% weight loss compared to 13.7% with semaglutide over 72 weeks.

How are the dosing schedules different?

Both medications are injected once weekly under the skin. Wegovy is available in doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg. Zepbound is available in doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Each has a gradual dose escalation schedule to minimize side effects.

What are the common side effects of each?

Both medications share similar gastrointestinal side effects. The most common include nausea, diarrhea, vomiting, constipation, abdominal pain, and decreased appetite. These side effects are usually mild to moderate and often improve over time. In trials, about 4% to 8% of people discontinued either drug due to side effects.

How do costs and insurance coverage compare?

Both medications are brand name and expensive without insurance. Wegovy was approved in 2021 and may have more established coverage for weight loss. Zepbound was approved in 2023 and coverage is growing. Manufacturer savings programs are available for eligible patients. Typical list prices are around $1,000 to $1,300 per month, but insurance can reduce out of pocket costs.

Frequently Asked Questions

Can I switch from Wegovy to Zepbound?

Switching between these medications is possible but should only be done under a healthcare provider’s guidance. There are no standard switching protocols, and doctors may need to adjust dosing to avoid side effects. It is also important to note that Wegovy and Zepbound have different titration schedules, so a direct dose conversion is not recommended.

Which medication is better for weight loss maintenance?

Both medications are approved for chronic weight management, meaning they are intended for long term use. Long term trials for Zepbound (SURMOUNT-4) show that continuing treatment maintains weight loss, while stopping leads to regain. Similar results have been seen with Wegovy. Choosing between them should be based on individual response, side effect profile, and cost, as both are effective for maintenance.

Are Zepbound and Wegovy safe for people with type 2 diabetes?

Yes, but there are specific considerations. Zepbound and Wegovy are not approved for type 2 diabetes alone; they are approved for weight management. However, both can improve blood sugar control. People with diabetes should monitor their blood sugar closely, as these medications can lower it and may require adjustments to diabetes medications. Zepbound carries a stronger warning for diabetic retinopathy risk in people with type 2 diabetes.

This article is for general information and is not medical advice. See our Medical Disclaimer.